DNA Methylation and Cancer Development: Molecular Mechanism

Cell Biochemistry and Biophysics

Volumn 67, Issue 2, 2013, Pages 501-513

  Akhavan Niaki, Haleh ^a   Samadani, Ali Akbar ^a  

^a BABOL UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cancer; DNA methylation; Epigenetics; Histone modification; MicroRNA; Oncogenesis

Indexed keywords

FOLIC ACID; HISTONE;

ANIMAL; CARCINOGENESIS; DNA METHYLATION; GENETICS; HUMAN; METABOLISM; MUTATION; NEOPLASM; PATHOLOGY; REVIEW;

ANIMALS; CARCINOGENESIS; DNA METHYLATION; FOLIC ACID; HISTONES; HUMANS; MUTATION; NEOPLASMS;

EID: 84886591519     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-013-9555-2     Document Type: Review

References (135)

1. Law, J. A., Jacobsen, S. E (2010). Establishing, maintaining and modifying DNA methylation patterns in plants and animals.
2. Docherty, S. J., Davis, O. S., Haworth, C. M. M., Plomin, R., & Mill, J. (2010). DNA methylation profiling using bisulfite-based epityping of pooled genomic DNA. Methods, 52, 255-258.
3. Singal, R., & Ginder, G. D. (1999). DNA methylation. Blood, 93, 4059-4070.
4. Laird, P. W. (2003). The power and the promise of DNA methylation markers. Nature Reviews Cancer, 3, 253-266.
5. Baylin, S. B. (1997). Tying it all together: Epigenetics, genetics, cell cycle, and cancer. Science, 277, 1948-1949.
6. Costello, J. F., & Plass, C. (2001). Methylation matters. Journal of Medical Genetics, 38, 285-303.
7. Baylin, S. B. (1997). Tying it all together: Epigenetics, genetics, cell cycle, and cancer. Science, 277, 1948-1949.
8. Cooper, D. N. & Krawczak, M. (1990). Human Genetics 83, 181-188.
9. Bestor, T. H (1992). Embo G11, 2611-2617.
10. Ehrlich, M., Zhang, X, Y. & Inamdar, N. M. (1990) Mutatation Research238, 277-286.
11. Bedford, M. T. & van Helden, P. D. (1987) Cancer Research47, 5274-5276.
12. Bestor, T., Laudano, A., Mattaliano, R. & Ingram, V. (1988) G Molecular Biology203, 971-983.
13. Fremont, M., Siegmann, M., Gaulis, S., et al. (1997). Demethylation of DNA by purified chick embryo 5-methylcytosine-DNA glycosylase requires both protein and RNA. Nucleic Acids Research, 25, 2375-2380.
14. Wade, P. A., Gegonne, A., Jones, P. L., et al. (1999). Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation. Nature Genetics, 23, 62-66.
15. Rhee, I., Bachman, K. E., Park, B. H., et al. (2002). DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature, 416, 552-556.
16. Paroush, Z., Keshet, I., Yisraeli, G. & Cedar, H. (1990). Cell63, 1229-1237.
17. Monk, M., Adams, R. L. & Rinaldi, A. (1991) Development112, 189-192.
18. Yen, R. W., Campbell, T. A., Nelkin, B. D., Yu, J., Jel, D. W., Cumaraswamy, A., Lennon, G. G., Trask, B. J., Celano, P. & Baylin, S. B. (1992) Nucleic Acids Research 20, 2287-2291.
19. Vairapandi, M. & Duker, N. J. (1993) Nucleic Acids Research 21, 5323-5327.
20. Singer, S. J. & Riggs, A. D. (1993) In Jost, J. P. and Saluz, H. P. (ed.), DNA Methylation: molecular biology and biological significance. BirkhauserVerlag, Basel (Switzerland). pp. 358-384.
21. Wu, J. C. & Santi, D. V. (1987) Journal Biological Chemistry 262, 4778-4786.
22. Rideout, W. III., Coetzee, G. A., Olumi, A. F. & Jones, P. A. (1990) Science 249, 1288-1290.
23. Das P. M., Rakesh, S. (2004) DNA Methylation and cancer.
24. Lam, A. K. Y. (2000). Molecular biology of esophageal squamous cell carcinoma. Critical Reviews in Oncology/Hematology, 33, 71-90.
25. Parkin, D. M., Baray, F., Ferlay, J., & Pisanl, P. (2001). Estimating the world cancer burden: Globocan 2000, International Journal of cancer, 94(2), 153-156.
26. Ducasse, M., & Brown, M. A. (2006). Epigenetic aberrations and cancer. Molecular Cancer, 5, 60.
27. Ohki, L., Shimotake, N., Fujita, N., Jea, J., Ikegami, T., & Nakao, M. (2001). Solution structure of the methly - CpG binding domain of human MBD1 in complex with methylated DNA. Cell, 105, 487-497.
28. Ng, H. H., & Bird, A. (1999). DNA methylation and chromatin modification. Current Opinion in Genetics & Development, 9, 158-163.
29. Costello, J. F. (2001). PlassC: Methylation matters. Journal of Medical Genetics, 38, 285-303.
30. Ordway, J. M., & Curran, T. (2002). Methylation matters: Modeling a manageable genome. Cell Growth & Differentiation, 13, 149-162.
31. Flanagan, H. M., Munoz-Alegre, M., Henderson, S. M., Tang, T., Sun, P., Johnson, N., et al. (2009). Gene-body hypermethylation of ATM in peripheral blood DNA of bilateral breast cancer patients. Human Molecular Genetics, 18, 1332-1342.
32. Moore, L. E., Pfeiffer, R. M., Poscablo, C., Real, F. X., Kogevinas, M., Silverman, D., et al. (2008). Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder cancer study: A case-control study. Lancet Oncol, 9, 359-366.
33. Lim, U., Flood, A., Choi, S. W., Alanes, D., Cross, A. J., Schatzkinm, A., et al. (2008). Genomic methylation of leukocyte DNA in relation to colorectal adenoma among asymptomatic women. Gastroenterology, 134, 47-55.
34. Widschwendter, M., Apostolidou, S., Raum, E., Rothenbacher, D., Fiegl, H., Menon, U., et al. (2008). Epigenotyping in peripheral blood cell DNA and breast cancer risk: A proof of principle study. PLoS ONE, 3, e2656.
35. Ally, M. S., Al-Ghnaniem, R., & Pufulete, M. (2009). The relationship between gene-specific DNA methylation in leukocytes and normal colorectal mucosa in subjects with and without colorectal tumors. Cancer Epidemiology, Biomarkers and Prevention, 18, 922-928.
36. Teschendorff, A. E., Menon, U., Gayther, S. A., Ramus, S. J., Gentry -Maharaj, A., Apostolidou, S., et al. (2009). An epigenetic signature in peripheral blood predicts active ovarian cancer. PLoS ONE, 4, e8274.
37. Pedersen, K. S., Bamlet, W. R., Oberg, A. L., de Anderade, M., Matsumoto, M. E., Tang, H., et al. (2011). Leukocyte DNA methylation signature differentiates pancreatic cancer patients from healthy controls. PLoS ONE, 6, e18223.
38. Kristensen, L. S., & Hansen, L. L. (2009). PCRP-based methods for detecting single-loci DNA methylation biomarkers in cancer diagnostics, prognostics, and response to treatment. Clinical Chemistry, 55, 1471-1483.
39. Bibikova, M., & Fan, J. B. (2010). Genome-wide DNA methylation profiling. Wiley Interdisciplinary Reviews Systems Biology and Medicine, 2, 210-223.
40. Gupta, R., Nagarajan, A., Wajapeyee, N. (2010) Advances in genome-wide DNA methylation analysis. Biotechniques 49, iii-xi.
41. Bock, C., Tomazou, E. M., Brinkman, A. B., Meller, F., Simmer, F., Gu, H., et al. (2010). Quantitative comparison of genome-wide DNA methylation mapping technologies. Nature of Biotechnology, 28, 1106-1114.
42. Bibikova, M., Le, J., Barnes, B., Saedinia-Melnyk, S., Zhou, L., Shen, R., et al. (2009). Genome-wide DNA methylation profiling using infinium assay. Epigenomics, 1, 177-200.
43. Yuasa, Y. (2010). Epigenetics in molecular epidemiology of cancer a new scope. Advances Genetics, 71, 211-235.
44. Brait, M., Ford, J. G., Papaiahgari, S., Garza, M. A., Lee, J. I., Loyo, M., et al. (2009). Association between lifestyle factors and CpG island methylation in a cancer-free population. Cancer Epidemiology, Biomarkers and Prevention, 18, 2984-2991.
45. Techendorff, A. E., Menon, U., Gentry-Maharaj, A., Ramus, S. J., Weisenberger, D. J., Shen, H., et al. (2010). Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Research, 20, 440-446.
46. Breitling, L. P., Yang, R., Korn, B., Burwinkel, B., & Brenner, H. (2011). Tobacco-smoking-related differential DNA methylation: 27 k discovery and replication. The American Journal of Human Genetics, 88, 450-457.
47. Terry, M. B., Delgado-Cruzata, L., Vin-Raviv, N., Wu, H. C., & Santella, R. M. (2011). DNA methylation in white blood cells: Association with risk factors in epidemiologic studies. Epigenetics, 6, 828-837.
48. Terry, M. B., Ferris, J. S., Pilsner, R., Flom, J. D., Tehranifar, P., Santella, R. M., et al. (2008). Genomic New York City birth cohort. Cancer Epidemiology, Biomarkers and Prevention, 17, 2306-2310.
49. Zhang, F. F., Morabia, A., Carroll, J., Gonzalez, K., Fulda, K., Kaur, M., et al. (2011). Dietary patterns are associated with levels of global genomic DNA methylation in a cancer-free population. The Journal of Nutrition, 141, 1165-1171.
50. Wang, X., Zhu, H., Snieder, H., Su, S., Munn, D., Harshfield, G., et al. (2010). Obesity related methylation changes in DNA of peripheral blood leukocytes. BMC Medicine, 8, 87.
51. Zhang, F. F., Cardarelli, R., Zhang, F. F., Carroll, J., Fulda, K. G., Gonzalez, K., et al. (2011). Physical activity and global genomic DNA methylation in a cancer-free population. Epigenetics, 6, 293-299.
52. van der Auwera, I., Elst, H. J., van Laere, S. J., Maes, H., Huget, P., van Dam, P., et al. (2009). The presence of circulating total DNA and methylated genes is associated with circulationg tumour cells in blood from breast cancer patients. British Journal of Cancer, 100, 1277-1286.
53. Yazici, H., Terry, M. B., Cho, Y. H., Senie, R. T., Liao, Y., Andrulis, I., et al. Aberrant methylation of RASSFIA in plasma DNA before breast cancer diagnosis in the Breast Cancer Family Registry.
54. Wang, Y. C., Yu, Z. H., Lio, C., Xu, L. Z., Yu, W., Lu, J., et al. (2008). Detection of RASSFIA promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients. World Journal of Gastroenterology, 14, 3074-3080.
55. Ellinger, J., Haan, K., Heukamp, L. C., Kahl, P., Meller, S. C., et al. (2008). CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer. Prostate, 68, 42-49.
56. Lofton-Day, C., Model, F., Devos, T., Tetzner, R., Distler, J., Schuster, M., et al. (2008). DNA Methylation biomarkers for blood-based colorectal cancer screening. Clinical Chemistry, 54, 414-423.
57. Gobel, G., Auer, D., Gaugg, I., Schneitter, A., Lesche, R., Muller-Holzner, E., et al. (2011). Prognostic significance of methylated RASSFIA and PITX2 genes in blood-and bone marrow plasma of breast cancer patients. Breast Cancer Research and Treatment, 130(1), 109-117.
58. Sunami, E., Shinozaki, M., Higano, C. S., Wollman, R., Dorff, T. B., Tucker, S. J., et al. (2009). Multimarker circulating DNA assay for assessing blood of prostate cancer patients. Clinical Chemistry, 55, 559-567.
59. Lee, B. B., Lee, E. J., Jung, E. H., Chun, H. K., Chang, D. K., Song, S. Y., et al. (2009). Aberrant methylation of APC, MGMT, RASSF2A, and Wif-l genes in plasma as a biomarker for early detection of colorectal cancer. Clinical Cancer Research, 15, 6185-6191.
60. Kaaks, R., Stattin, P., Villar, S., Poetsch, A. R., Dossus, L., Nieters, A., et al. (2009). Insulin-like growth factor-II methylation status in lymphocyte DNA colon cancer risk in the Northern Sweden health and disease cohort. Cancer Research, 69, 5400-5405.
61. Cash, H. L., Tao, L., Yuan, J. M., Marsit, C. J., Houseman, E. A., Xiang, Y. B., et al. (2012). LINE-l hypomethylation is associated with bladder cancer risk among non-smoking Chinese. International Journal of Cancer, 130(5), 1151-1159.
62. Wang, L., Aakre, J. A., Jiang, R., Marks, R. S., Eu, Y., Chen, J., et al. (2010). Methylation markers for small cell lung cancer in peripheral blood leukocyte DNA. Journal of Thoracic Oncology, 5, 778-785.
63. Al-Moundhri, M. S., Al-Nabhani, M., Tarantini, L., Baccarelli, A., & Rusiecki, J. A. (2010). The prognostic significance of whole blood global and specific DNA methylation levels in gastric adenocarcinoma. PLoS ONE, 5, e15585.
64. Tierling, S., Schuster, M., Tetzner, R., & Walter, J. (2010). A combined HM-PCR/SNuPE method for high sensitive detection of rare DNA methylation. Epigenetics and Chromatin, 3, 12.
65. Radpour, R., Barekati, Z., Kohler, C., Lv, Q., Burki, N., Diesch, C., et al. (2011). Hypermethylation of tumor suppressor genes involved in critical regulatory pathways for developing a blood-based test in breast cancer. PLoS ONE, 6, e16080.
66. De Vos, T., Tetzner, R., Model, F., Weiss, G., Schuster, M., Distler, J., et al. (2009). Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clinical Chemistry, 55, 1337-1346.
67. Melnikov, A. A., Scholtens, D., Talamonti, M. S., Bentrem, D. J., & Levenson, V. V. (2009). Methylation profile of circulating plasma DNA in patients with pancreatic cancer. Journal of Surgical Oncology, 99, 119-122.
68. Cho, Y. H., Yazici, H., Wu, H. C., Terry, M. B., Gonzalez, K., Qu, M., et al. (2010). Aberrant promoter hypermethylation and genomic hypomethylation in tumor, adjacent normal tissues and blood from breast cancer patients. Anticancer Research, 30, 2489-2496.
69. Wilhelm, C. S., Kelsey, K. T., Butler, R., Plaza, S., Zens, M. S., et al. (2010). Implications of LINE1 methylation for bladder cancer risk in women. Clinical Cancer Research, 16, 1682-1689.
70. Pinheiro, H., Bordeira-Carrico, R., Seixas, S., Carvalho, J., Senz, J., Oliveira, P., et al. (2010). Allele-specific CDHl downregulation and hereditary diffuse gastric cancer. Human Molecular Genetics, 19, 943-952.
71. Wilson, A. S., Power, B. E., & Molloy, P. L. (2007). DNA hypomethylation and human diseases. Biochimica et Biophysica Acta, 1775(1), 138-162.
72. Paredes, J., Albergaria, A., Oliveira, J. T., Jeronimo, C., Milanezi, F., & Schmitt, F. C. (2005). P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Clinical Cancer Research, 11(16), 5869-5877.
73. Liu, H., Liu, W., Eu, Y., et al. (2005). Loss of epigenetic control of synuclein-γ as a molecular indicator of metastasis in a wide range of human cancers. Cancer Research, 65(17), 7635-7643.
74. Woodson, K., Mason, J., Choi, S. W., et al. (2001). Hypomethylation of p53 in peripheral blood DNA is associated with the development of lung cancer. Cancer Epidemiology, Biomarkers and Prevention, 10(1), 69-74.
75. Callinan, P. A., & Feinberg, A. P. (2006). The emerging science of epigenomics. Human Molecular Genetics, 15(Spec. No. 1), R95-R101.
76. Yang, A. S., Estecio, M. R., Doshi, K., Kondo, Y., Tajara, E. H., & Issa, J. P. (2004). A simple method for edtrimating global DNA methylation using bisulfit PCR of repetitive DNA elements. Nucleic Acids Research, 32(3), e38.
77. Ogino, S., Nosho, K., Kirkner, G. J., et al. (2008). A cohort study of tumoral line-1 hypomethylation and prognosis in colon cancer. Journal National Cancer Institute, 100(23), 1734-1738.
78. Irahara, N., Nosho, K., Baba, Y., et al. (2010). Precision of pyrosequencing assay to measure lin-1 methylation in colon cancer, normal colonic mucosa, and peripheral blood cells. The Journal of Molecular Diagnostics, 12(2), 177-183.
79. Lee, Y., Ahn, C., Han, H., et al. (2003). The nuclear RNase III drosha initiates micron processing. Nature, 425(6956), 415-419.
80. Lund, E., Guttinger, S., Calado, A., et al. (2004). Nuclear export of micron precursors. Science, 303(5654), 95-98.
81. Nilsen, T. W. (2007). Mechanisms of micron-mediated gene regulation in animal cells. Trends of Genetics, 23(5), 243-249.
82. Wiemer, E. A. (2007). The role of micronas in cancer: no small matter. European Journal of Cancer, 43(10), 1529-1544.
83. Michael, M. Z., SM, O. C., van Holst Pellekaan, N. G., et al. (2003). Reduced accumulation of specific micronas in colorectal neoplasia. Cancer Research, 1(12), 882-891.
84. Kitade, Y., & Akao, Y. (2010). Micronas and their therapeutic potential for human diseases micronas, mir-143 and -145 function as anti-oncomirs and the application of chemically modified mir-143 as an anti-cancer drug. Journal of Pharmacology Science, 114(3), 276-280.
85. Ng, E. K., Chong, W. W., Jin, H., et al. (2009). Differential expression of micronas in plasma of patients with colorectal cancer: A potential marker for colorectal cancer screening. Gut, 58(10), 1375-1381.
86. Koga, Y., Yasunaga, M., & Takahashi, A. (2010). Microna expression profiling of exfoliated colonocytes isolated from feces for colorectal cancer screening. Cancer Prevention Research (Philadelphia, Pa.), 3(11), 1435-1442.
87. Lagos-Quintana, M., Rauhut, R., Lendeckel, W., et al. (2001). Identification of novel genes coding for small expressed rnas. Science, 294(5543), 853-858.
88. Wang, C. J., Zhoi, Z. G., Wang, L., et al. (2009). Clinicopathological significance of micronas-31,-143 and -145 expression in colorectal cancer. Disease Markers, 26(1), 27-34.
89. Slaby, O., Svoboda, M., Fabian, P., et al. (2007). Altered expression of mir-21, mir-31, mir-143 and mir-145 is related to cliniccopathologic features of colorectal cancer [J]. Oncology, 72(5-6), 397-402.
90. Wang, C. J., Stratmann, J., Zhou, Z. G., et al. (2010). Suppression of micron-31 increases sensitivity to 5-FU at an early stage, and affects cell migration and invasion in HCT-116colon cancer cells. BMC Cancer, 10, 616.
91. Cheng, H., Zhang, L., Cogdell, D. E., et al. (2011). Circulating plasma mir-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS ONE, 6(3), e17745.
92. Schepeler, T., Reinert, J. T., Ostenfeld, M. S., et al. (2008). Diagnostic and prognostic micronas in stage II colon cancer. Cancer Research, 68(15), 6414-6424.
93. Schetter, A. J., Leung, S. Y., Sohn, J. J., et al. (2008). Microna expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA, 299(4), 425-436.
94. Volinia, S., Calin, G. A., Liu, C. G., et al. (2006). A micron expression signature of human solid tumors defines cancer gene targets [J]. Proceedings of the National Academy of Sciences of the United States of America, 103(7), 2257-2261.
95. Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003). 5-fluorouracil: Mechanisms of action and clinical strategies. Nature Review Cancer, 3(5), 330-338.
96. Schetter, A. J., Nguyen, G. H., Bowmen, E. D., et al. (2009). Association of inflammation-related and micron gene expression with cancer-specific mortality of colon adenocarcinoma. Clinical Cancer Research, 15(18), 5878-5887.
97. Bandres, E., Agirre, X., Bitarte, N., et al. (2009). Epigenetic regulation of micron expression in colorectal cancer. International Journal of Cancer, 125(11), 2737-2743.
98. Balaguer, F., Link, A., Lozano, J. J., et al. (2010). Epigenetic silencing of mir-137 is an early event in colorectal carcinogenesis. Cancer Research, 70(16), 6609-6618.
99. Saito, Y., Liang, G., Egger, G., et al. (2006). Specific activation of microrna-127 with downregulation of the proto-oncogene bcl6 by chromatin-modifying drugs in human cancer cells. Cancer Cell, 9(6), 435-443.
100. Lujambio, A., Ropero, S., Ballestar, E., et al. (2007). Genetic unmasking of an epigenetically silenced microrna in human cancer cells [J]. Cancer Research, 67(4), 1424-1429.
101. Berger, S. L. (2002). Histone modifications in transcriptional regulation. Current Opinion in Genetics & Development, 12(2), 142-148.
102. Barski, A., Cuddapah, S., Cui, K., et al. (2007). High-resolution profiling of histone methylations in the human genome. Cell, 129(4), 823-837.
103. Litt, M. D., Simpson, M., Gaszner, M., et al. (2001). Correlation between histone lysine methylation and developmental changes at the chicken beta-globin locus [J]. Science, 293(5539), 2453-2455.
104. Noma, L., Allis, C. D., & Grewal, Sl. (2001). Transitions in distinct histone H3 methylation patterns at the heterochromatin domain boundaries. Science, 293(5532), 1150-1155.
105. Richon, V. M., Sandhof, T. W., Rifkind, R. A., et al. (2000). Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proceedings of the National Academy of Sciences of the United States of America, 97(18), 10014-10019.
106. Pruitt, K., Zinn, R. L., Ohm, J. E., et al. (2006). Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genetics, 2(3), e40.
107. Tsang, D. P. F., & Cheng, A. S. L. (2011). Epigenetic regulation of signaling pathways in cancer: Role of the histone methyltransferase EZH2. Journal of Gastroenterolhepatology, 26(1), 19-27.
108. Pelaez, I. M., Kalogeropoulou, M., Ferraro, A., et al. (2010). Oncogenic ras alters the global and gene-specific histone modification pattern during epithelial-mesenchymal transition in colorectal carcinoma during epithelial-mesenchymal transition in colorectal carcinoma cells. Biology International, 42(6), 911-920.
109. Baylin, S. B., & Herman, J. G. (2000). DNA hypermethylation in tumorigenesis: Epigenetics joins [J]. Trends Genetics, 16(4), 168-174.
110. Jones, P. A., & Laird, P. (1999). Cancer epigenetics comes of age. Nature Genetics, 21(2), 163-167.
111. Jenuwein, T., & Allis, C. D. (2001). Translating the histone code. Science, 293(5532), 1074-1080.
112. Tamaru, H., & Selkar, E. R. (2001). A histone H3 methyltransferase controls DNA methylation in neurosporacrassa. Nature, 414(6861), 277-283.
113. Jackson, J. P., Lindroth, A. M., Cao, X., et al. (2002). Control of cpnpg DNA methylation by the kryptonite histone H3 methyltransferase. Nature, 416(6880), 558-560.
114. Herman, J. G., Umar, A., Polyak, K., et al. (1998). Incidence and functional consequences of HMLH promoter hypermethylation in colorectal carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 95(12), 6870-6875.
115. Farhrner, J. A., Eguchi, S., Herman, J. G., et al. (2002). Dependence of histone modification and gene expression on DNA hypermethylation in cancer. Cancer Research, 62(24), 7213-7218.
116. Valenzuela, M. T., Galisteo, R., Zuluaga, A., Villalobos, M., Nunez, M, I., Oliver, F. J., et al. (2002). Assessing the use of p16INK4a promoter gene methylation in serum for detection of bladder cancer. European Urology 42: 622-628, discussion 628-630.
117. Leung, W. K., To, K. F., Chu, E. S., Chan, M. W., Bai, A. H., Ng, E. K., et al. (2005). Potential diagnostic and prognostic values of detecting promoter hypermethylation in the serum of patients with gastric cancer. British Journal of Cancer, 92, 2190-2194.
118. Wong, T. S., Man, M. W., Lam, A. K., Wei, W. I., Kwong, Y. L., & Yuen, A. P. (2003). The study of p16 and p15 gene methylation in head and neck squamous cell carcinoma and their quantitative evaluation in plasma by real-time PCR. European Journal of Cancer, 39, 1881-1887.
119. Fujiwara, K., Fujimoto, N., Tabata, M., Nishii, K., Matsuo, K., Hotta, K., et al. (2005). Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clinical Cancer Research, 11, 1219-1225.
120. Wong, T. S., Kwong, D. L., Sham, J. S., Wei, W. I., Kwong, Y. L., & Yuen, A. P. (2004). Quantitative plasma hypermethylation DNA markers of undifferentiated nasopharyngeal carcinoma. Clinical Cancer Research, 10, 2401-2406.
121. Reibenwein, J., Pils, D., Horak, P., Tomicek, B., Goldner, G., Worel, N., et al. (2007). Promoter hypermethylation of GSTPI, AR, and 14-3-3 sigma in serum of prostate cancer patients and is clinical relevance. Prostate, 67, 427-432.
122. Fiegl, H., Millinger, S., Mueller-Holzner, E., Marth, C., Ensinger, C., Berger, A., et al. (2005). Circulating tumor-specific DNA: A marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Research, 65, 1141-1145.
123. Muller, H. M., Widschwendter, A., Fiegl, H., Ivarsson, L. M., Goebel, G., Perkmann, E., et al. (2003). DNA methylation in serum of breast cancer patients: An independents prognostic marker. Cancer Research, 63, 7641-7645.
124. Dominguez, G., Carballido, J., Silva, J., Silva, J. M., Garcia, J. M., Menendez, J., et al. (2002). p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients. Clinical Cancer Research, 5, 980-985.
125. Widschwendter, A., Muller, H. M., Fiegl, H., Ivarsson, L., Wirdemair, A., Muller-Holzner, E., et al. (2004). DNA methylation in serum and tumors of cervical cancer patients. Clinical Cancer Research, 10, 565-571.
126. Widschwendter, A., Ivarsson, L., Blassnig, A., Muller, H. M., Fiegl, H., Wiedemair, A., et al. (2004). CDH1 and CDH13 methylation in serum is an independent prognostic marker in cervical cancer patients. International Journal of Cancer, 109, 163-166.
127. Wallner, M., Herbst, A., Behrens, A., Crispin, A., Stieber, P., Goke, B., et al. (2006). Methylation of serum DNA is an independent prognostic marker in colorectal cancer. Clinical Cancer Research, 12, 7347-7352.
128. Hoffmann, A. C., Kaifi, J. T., Vallbohmer, D., Yekebas, E., Grimminger, P., Leers, J. M., et al. (2009). Lack of prognostic significance of serum DNA methylation of DAPK, MGMT, and GSTPI in patients with non-small cell lung cancer. Journal of Surgical Oncology, 100, 414-417.
129. Kawakami, K., Brabender, J., Lord, R. V., Groshen, S., Greenwaid, B. D., Krasna, M. J., et al. (2000). Hypermethylation APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. Journal of National Cancer Research, 92, 1805-1811.
130. Tangkijvanich, P., Hourpai, N., Rattanatanyong, P., Wisedopas, N., Mahachai, V., & Multirangura, A. (2007). Serum LINE-1 hypomethylation as a potential prognostic marker for hepatocellular carcinoma. Clinical Cancer Acta, 379, 127-133.
131. Ramirez, J. L., Rosell, R., Taron, M., Sanchez-Ronco, M., Alberola, V., Las de Penas, R., et al. (2005). 14-3-3 {sigma}methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group. Journal of Clinical Oncology, 23, 9105-9112.
132. Gifford, G., Paul, J., Vasey, P. A., Kaye, S. B., & Brown, R. (2004). The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clinical Cancer Research, 10, 4420-4426.
133. Bastian, P. J., Palapattu, G. S., Lin, X., Yegnasubrammanian, S., Mangold, L. A., Trock, B., et al. (2005). Preoperative serum DNA GSTPI CpG island hypermethylation and the risk of early prostatic-specific antigen recurrence following radical prostatectomy. Clinical Cancer Research, 11, 4037-4043.
134. Hoque, M. O., Feng, Q., Toure, P., Dem, A., Critchlow, C. W., Hawes, S. E., et al. (2006). Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. Journal of Clinical Oncology, 24, 4262-4269.
135. Zhang, Y. J., Wu, H. C., Shen, J., Ahsan, H., Tsai, W. Y., Yang, H. I., et al. (2007). Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clinical Cancer Research, 13, 2378-2384.